A multicenter, double-blind, randomized, placebo-controlled trial for the effect of traditional Chinese medicine formula Dingkun pill on improving outcomes of IVF-ET in women with low prognosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR1900002673

Enrollment

Unknown

Registered

2019-10-16

Start date

2019-11-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low prognosis

Interventions

Placebo group:Placebo should be administered on the 5th day of the menstrual cycle prior to controlled ovarian stimulation (COH), 7g each time, 3 times per day, until the oocyte retrieval day, a total

DKP group:Dingkun pill should be administered on the 5th day of the menstrual cycle prior to controlled ovarian stimulation (COH), 7g each time, 3 times per day, until the oocyte retrieval day, a tota

Eligibility

Sex/Gender

Female

Age

35 Years to 44 Years

Inclusion criteria

Inclusion criteria: Participants aged 35 to 44 years with poor prestimulation ovarian reserve parameters (AFC<5, AMH<1.2 ng/mL) and with an expected poor ovarian response which means fewer than four oocytes were retrieved after standard ovarian stimulation, will be recruited in this study.

Exclusion criteria

Exclusion criteria: BMI >= 30 Kg/m2, karyotyping abnormalities in both partners, endometriosis, hydrosalpinx, congenital or acquired dysplasia of the uterus and other contraindications for assisted reproductive technology.

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy outcome;	—

Secondary

Measure	Time frame
Implantation rate;Early miscarriage rate;	—

Countries

China

Contacts

Public ContactZhengao Sun

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

sunzhengao77@126.com+86 13708938621

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026